focus -WSS

focus

author：leisure time 2025-09-30 16:27:45 - browse：2

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Free medical tuition alone isn't enough to close gaps in primary care

explore

WSS

STAT series 'Denied by AI' wins major journalism prizes

The White House hikes tariffs on plastic syringes made in China

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Oak Street deal isn't the answer to health care's woes

For BCIs, commercial hurdles may be bigger than scientific ones

explore

focus

focus

Hollywood unions extend contract negotiations for actors

A cyberattack has disrupted hospitals and health care in several states

DIEP, the 'gold standard' of breast reconstruction, is under threat

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Medical records are filled with copy

WuXi Biologics beefs up its lobbying operation

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Medical leaders decry Supreme Court decision on affirmative action

Obesity drug from Roche shows promise in early study

hotspot

Dramatically reducing cancer deaths requires the PASTEUR Act

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Gilgo Beach: Police identify another victim in serial killing investigation

HHS suspends federal funding for EcoHealth Alliance

Stem cell clinics for heart failure: buyer be wary

entertainment

explore

focus

focus